MCID: CLR030
MIFTS: 53

Clear Cell Renal Cell Carcinoma malady

Categories: Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Clear Cell Renal Cell Carcinoma

Aliases & Descriptions for Clear Cell Renal Cell Carcinoma:

Name: Clear Cell Renal Cell Carcinoma 50
Clear-Cell Metastatic Renal Cell Carcinoma 50 69
Conventional Renal Cell Carcinoma 69
Cystic-Multilocular Variant 50
Clear Cell Rcc 50

Classifications:



Summaries for Clear Cell Renal Cell Carcinoma

NIH Rare Diseases : 50 clear cell renal cell carcinoma is a cancer of the kidney.  the name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope.  clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass).  though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von hippel lindau syndrome) may contribute to the development of this type of cancer.  treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy. last updated: 6/1/2012

MalaCards based summary : Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to renal clear cell carcinoma and testicular cancer, and has symptoms including flank pain An important gene associated with Clear Cell Renal Cell Carcinoma is PBRM1 (Polybromo 1), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Sunitinib and Axitinib have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 71 The Clear Cell Renal Cell Carcinoma (CCRCC) is a type of Renal cell... more...

Related Diseases for Clear Cell Renal Cell Carcinoma

Diseases related to Clear Cell Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
id Related Disease Score Top Affiliating Genes
1 renal clear cell carcinoma 31.9 FLCN MET RNF139
2 testicular cancer 29.3 CCND1 EGFR KDR MET TP53 VEGFA
3 multilocular clear cell renal cell carcinoma 12.1
4 renal cell carcinoma 12.1
5 clear cell papillary renal cell carcinoma 11.3
6 multilocular cystic clear cell renal cell neoplasm of low malignant potential 11.1
7 von hippel-lindau syndrome 11.0
8 birt-hogg-dube syndrome 11.0
9 endotheliitis 10.4
10 hypoxia 10.3
11 generalized eruptive keratoacanthoma 10.3 CA9 PBRM1 VHL
12 hole retinal cyst 10.3 CA9 HIF1A KDR
13 well-differentiated thymic neuroendocrine carcinoma 10.3 BAP1 TP53
14 neuropathy with hearing impairment 10.2 KDR VEGFA VHL
15 acute posterior multifocal placoid pigment epitheliopathy 10.2 HIF1A VEGFA VHL
16 sacrococcygeal teratoma 10.2 HIF1A SETD2 VEGFA
17 wolffian adnexal neoplasm 10.2 EGFR TP53
18 hemangioblastoma 10.2
19 oppositional defiant disorder 10.2 HIF1A KDR VEGFA
20 atrioventricular septal defect 2 10.2 EPAS1 HIF1A VHL
21 benign familial neonatal epilepsy 10.2 EGFR KDR VEGFA
22 immunodeficiency due to a late component of complement deficiency 10.2 EGFR TP53 VEGFA
23 endocervicitis 10.2 BCL2 HIF1A VEGFA
24 complement deficiency 10.2 FLCN MET
25 pyloric antrum cancer 10.2 BCL2 TP53 VEGFA
26 multinodular goiter 10.2 EGFR KDR VEGFA
27 interstitial lung disease 10.2 EGFR TP53 VEGFA
28 human granulocytic anaplasmosis 10.2 KDR TP53 VEGFA
29 gallbladder papillomatosis 10.2 BCL2 TP53 VEGFA
30 male infertility 10.2 BCL2 CCND1
31 thanatophoric dysplasia, type ii 10.2 CA9 HIF1A RASSF1 TP53
32 cystitis 10.1 FLCN HIF1A TSC1
33 ganglioneuroblastoma 10.1 EGFR KDR MET
34 dental caries 10.1 EGFR TP53 VEGFA
35 nasal cavity disease 10.1 EGFR TP53 VEGFA
36 prostatic adenoma 10.1 EGFR TP53 VEGFA
37 rectum kaposi's sarcoma 10.1 EGFR FLCN HIF1A MET
38 angiomyolipoma 10.1
39 chromophobe renal cell carcinoma 10.1
40 childhood-onset cerebral x-linked adrenoleukodystrophy 10.1 EGFR RASSF1 TP53
41 vulvar proximal-type epithelioid sarcoma 10.1 BAP1 EGFR MET VEGFA
42 metagonimiasis 10.1 KDR MET TP53 VEGFA
43 estrogen-receptor positive breast cancer 10.1 CCND1 EGFR TP53
44 albinism, oculocutaneous, type ib 10.1 HIF1A KDR VEGFA
45 spastic paraplegia 1 10.1 BCL2 EGFR TP53 VEGFA
46 oral squamous cell carcinoma 10.1 EGFR TP53 VEGFA
47 marginal zone b-cell lymphoma 10.1 BCL2 EGFR TP53 VEGFA
48 mental retardation, autosomal recessive 27 10.1 KDR SERPINE1 VEGFA
49 obesity 10.1
50 central nervous system leiomyosarcoma 10.1 CA9 EPAS1 HIF1A VEGFA VHL

Graphical network of the top 20 diseases related to Clear Cell Renal Cell Carcinoma:



Diseases related to Clear Cell Renal Cell Carcinoma

Symptoms & Phenotypes for Clear Cell Renal Cell Carcinoma

UMLS symptoms related to Clear Cell Renal Cell Carcinoma:


flank pain

MGI Mouse Phenotypes related to Clear Cell Renal Cell Carcinoma:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.53 SERPINE1 SETD2 TP53 TSC1 VEGFA VHL
2 homeostasis/metabolism MP:0005376 10.44 EGFR EPAS1 FLCN HIF1A KDR MET
3 growth/size/body region MP:0005378 10.43 BAP1 BCL2 CCND1 EGFR EPAS1 FLCN
4 immune system MP:0005387 10.43 VEGFA VHL BCL2 CA9 CCND1 EGFR
5 hematopoietic system MP:0005397 10.42 BAP1 BCL2 CA9 CCND1 EGFR EPAS1
6 cellular MP:0005384 10.41 BAP1 BCL2 CCND1 EGFR FLCN HIF1A
7 mortality/aging MP:0010768 10.41 BAP1 BCL2 CA9 CCND1 EGFR EPAS1
8 embryo MP:0005380 10.39 TP53 TSC1 VEGFA VHL BAP1 EGFR
9 endocrine/exocrine gland MP:0005379 10.35 BAP1 BCL2 CA9 CCND1 EGFR HIF1A
10 digestive/alimentary MP:0005381 10.32 BAP1 BCL2 CA9 CCND1 EGFR HIF1A
11 liver/biliary system MP:0005370 10.26 EGFR EPAS1 HIF1A KDR MET PBRM1
12 integument MP:0010771 10.25 TP53 TSC1 VEGFA VHL BAP1 BCL2
13 craniofacial MP:0005382 10.24 BCL2 CCND1 EGFR HIF1A MET SETD2
14 neoplasm MP:0002006 10.22 BAP1 BCL2 CCND1 EGFR FLCN HIF1A
15 muscle MP:0005369 10.17 BAP1 BCL2 EGFR EPAS1 HIF1A KDR
16 nervous system MP:0003631 10.11 HIF1A KDR MET SETD2 TP53 TSC1
17 limbs/digits/tail MP:0005371 10.04 EGFR HIF1A MET SETD2 TP53 VEGFA
18 normal MP:0002873 9.97 CCND1 EGFR HIF1A KDR MET RASSF1
19 respiratory system MP:0005388 9.97 TP53 TSC1 VEGFA BAP1 BCL2 CCND1
20 renal/urinary system MP:0005367 9.96 HIF1A MET SERPINE1 TP53 TSC1 VEGFA
21 skeleton MP:0005390 9.65 EPAS1 HIF1A KDR SETD2 TP53 TSC1
22 vision/eye MP:0005391 9.4 TSC1 VEGFA VHL BCL2 CCND1 EGFR

Drugs & Therapeutics for Clear Cell Renal Cell Carcinoma

Drugs for Clear Cell Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
2
Axitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 319460-85-0 6450551
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
4
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
5
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1 946414-94-4
6 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
7 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
13 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
21
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
22
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
23
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
24
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
26
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
27
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
28
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
29
Paclitaxel Approved, Vet_approved Phase 3,Phase 1 33069-62-4 36314
30
Morphine Approved, Investigational Phase 3 57-27-2 5288826
31
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
32
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
33
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
34
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
35
Sulfamethoxazole Approved Phase 3 723-46-6 5329
36
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
37
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
39
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
40
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
41
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 59-67-6 938
42
Nicotinamide Approved, Nutraceutical Phase 3,Phase 1,Phase 2 98-92-0 936
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
44
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
45 interferons Phase 3,Phase 2,Phase 1
46 Alkylating Agents Phase 3,Phase 2,Phase 1
47 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
48 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
50 Etoposide phosphate Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 271)
id Name Status NCT ID Phase
1 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
2 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4
3 Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors Recruiting NCT02700568 Phase 4
4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Recruiting NCT02982954 Phase 4
5 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Recruiting NCT01521715 Phase 4
6 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4
7 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4
8 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3
9 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3
10 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
11 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
12 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
13 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3
14 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3
15 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3
16 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3
17 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
18 Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Completed NCT00678392 Phase 3
19 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
21 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
22 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
23 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Recruiting NCT02883153 Phase 2, Phase 3
24 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Recruiting NCT01575548 Phase 3
25 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Recruiting NCT02535351 Phase 3
26 Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Recruiting NCT03055013 Phase 3
27 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Recruiting NCT02928692 Phase 3
28 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Active, not recruiting NCT01668784 Phase 3
29 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Active, not recruiting NCT01599754 Phase 3
30 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01099423 Phase 3
31 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Active, not recruiting NCT01198158 Phase 3
32 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3
33 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Not yet recruiting NCT01762592 Phase 3
34 Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Not yet recruiting NCT03142334 Phase 3
35 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Unknown status NCT01069770 Phase 2
36 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2
37 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Unknown status NCT01216371 Phase 2
38 Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer Unknown status NCT01784978 Phase 2
39 Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery Unknown status NCT00293501 Phase 1, Phase 2
40 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status NCT00301990 Phase 2
41 A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy Unknown status NCT01693822 Phase 2
42 Immunochemotherapy for Metastatic Renal Cell Carcinoma Unknown status NCT00226798 Phase 2
43 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2
44 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2
45 Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients Unknown status NCT02324803 Phase 2
46 Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2
47 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Completed NCT01034631 Phase 1, Phase 2
48 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00244764 Phase 2
49 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). Completed NCT00796757 Phase 2
50 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2

Search NIH Clinical Center for Clear Cell Renal Cell Carcinoma

Genetic Tests for Clear Cell Renal Cell Carcinoma

Anatomical Context for Clear Cell Renal Cell Carcinoma

MalaCards organs/tissues related to Clear Cell Renal Cell Carcinoma:

39
Kidney, Endothelial, T Cells, Bone, Brain, Neutrophil, Prostate

Publications for Clear Cell Renal Cell Carcinoma

Articles related to Clear Cell Renal Cell Carcinoma:

(show top 50) (show all 856)
id Title Authors Year
1
A five-long non-coding RNA signature to improve prognosis prediction of clear cell renal cell carcinoma. ( 28512261 )
2017
2
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. ( 27939075 )
2017
3
Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. ( 28092369 )
2017
4
High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma. ( 28533485 )
2017
5
Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma. ( 27993630 )
2017
6
Downregulation of YAP in Clear Cell Renal Cell Carcinoma Contributes to Poor Prognosis and Progressive Features. ( 28249914 )
2017
7
Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. ( 28089832 )
2017
8
Comparison of biexponential and monoexponential DWI in evaluation of Fuhrman grading of clear cell renal cell carcinoma. ( 28050950 )
2017
9
Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. ( 28081542 )
2017
10
Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis. ( 28112366 )
2017
11
Downregulation of a novel long non-coding RNA, LOC389332, is associated with poor prognosis and tumor progression in clear cell renal cell carcinoma. ( 28450954 )
2017
12
CA9 as a biomarker in preoperative biopsy of small solid renal masses for diagnosis of clear cell renal cell carcinoma. ( 27775441 )
2017
13
Downregulation of OCLN and GAS1 in clear cell renal cell carcinoma. ( 28184927 )
2017
14
MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. ( 27907930 )
2017
15
Prognostic Value of Tissue Based Biomarker Signature in Clear Cell Renal Cell Carcinoma. ( 28075543 )
2017
16
Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma. ( 28076379 )
2017
17
Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma. ( 28089386 )
2017
18
Paratesticular Metastasis of a Clear-Cell Renal-Cell Carcinoma With Renal Vein Thrombus Mimicking Primary Testicular Cancer. ( 27450513 )
2016
19
Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2I+. ( 26943772 )
2016
20
Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma. ( 27485825 )
2016
21
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. ( 27568124 )
2016
22
BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation. ( 28070921 )
2016
23
The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma. ( 26855131 )
2016
24
Prognostic significance of ubiquinol-cytochrome c reductase hinge protein expression in patients with clear cell renal cell carcinoma. ( 27186431 )
2016
25
High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma. ( 27683054 )
2016
26
Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis. ( 27578234 )
2016
27
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. ( 27599260 )
2016
28
Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma. ( 26411550 )
2016
29
Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. ( 26300218 )
2016
30
Mutant versions of von Hippel-Lindau (VHL) can protect HIF1I+ from SART1-mediated degradation in clear-cell renal cell carcinoma. ( 25915846 )
2016
31
Loss of EphA3 Protein Expression Is Associated With Advanced TNM Stage in Clear-Cell Renal Cell Carcinoma. ( 27591824 )
2016
32
Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma. ( 27124015 )
2016
33
miR-206 functions as a novel cell cycle regulator and tumor suppressor in clear-cell renal cell carcinoma. ( 26808577 )
2016
34
Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins. ( 27468719 )
2016
35
miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. ( 27633984 )
2016
36
Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma. ( 27121191 )
2016
37
High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. ( 27564117 )
2016
38
Glycosaminoglycan Profiling in Patients' Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma. ( 27184840 )
2016
39
Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma. ( 27039779 )
2016
40
IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma. ( 26926076 )
2016
41
Voxel-based whole-lesion enhancement parameters: a study of its clinical value in differentiating clear cell renal cell carcinoma from renal oncocytoma. ( 27595574 )
2016
42
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. ( 27574806 )
2016
43
Long non-coding RNA Linc00152 is a positive prognostic factor for and demonstrates malignant biological behavior in clear cell renal cell carcinoma. ( 27186403 )
2016
44
Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma. ( 26797799 )
2016
45
Targeting HIF2 in Clear Cell Renal Cell Carcinoma. ( 27932568 )
2016
46
Podoplanin associates with adverse postoperative prognosis of patients with clear cell renal cell carcinoma. ( 27389969 )
2016
47
Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis. ( 26589610 )
2016
48
Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. ( 27108420 )
2016
49
Acanthosis Nigricans associated with clear-cell renal cell carcinoma. ( 27284539 )
2016
50
Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma. ( 27583351 )
2016

Variations for Clear Cell Renal Cell Carcinoma

Cosmic variations for Clear Cell Renal Cell Carcinoma:

9 (show top 50) (show all 981)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 21
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 21
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 21
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 21
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 21
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 21
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 21
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 21
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 21
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 21
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 21
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 21
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 21
14 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 15
15 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 15
16 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 15
17 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 15
18 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 15
19 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 15
20 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 15
21 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 15
22 COSM30715 WISP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.868T>C p.C290R 15
23 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 15
24 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 15
25 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 15
26 COSM14400 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>T p.S65L 15
27 COSM30293 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.586A>T p.K196* 15
28 COSM17734 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.304C>G p.P102A 15
29 COSM36358 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.341-11T>A p.? 15
30 COSM17658 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 15
31 COSM34007 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.227T>C p.F76S 15
32 COSM249280 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.264G>A p.W88* 15
33 COSM18023 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.486C>G p.C162W 15
34 COSM17875 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.234T>G p.N78K 15
35 COSM30212 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.202T>C p.S68P 15
36 COSM18276 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.406T>G p.F136V 15
37 COSM14407 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>C p.V130L 15
38 COSM18212 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.491A>C p.Q164P 15
39 COSM14311 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.499C>T p.R167W 15
40 COSM14380 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.548C>A p.S183* 15
41 COSM30295 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.341-2A>G p.? 15
42 COSM18015 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>A p.S65* 15
43 COSM18386 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.574C>T p.P192S 15
44 COSM18005 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.340+1G>A p.? 15
45 COSM17990 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463+2T>A p.? 15
46 COSM14397 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.490C>T p.Q164* 15
47 COSM17870 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.203C>T p.S68L 15
48 COSM17711 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.208G>T p.E70* 15
49 COSM30216 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.239G>A p.S80N 15
50 COSM3734682 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.280G>A p.E94K 15

Copy number variations for Clear Cell Renal Cell Carcinoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 135083 2 111395408 111435684 Copy number BUB1 Clear cell renal cell carcinoma
2 181389 4 120800000 123800000 Copy number MAD2L1 Clear cell renal cell carcinoma

Expression for Clear Cell Renal Cell Carcinoma

Search GEO for disease gene expression data for Clear Cell Renal Cell Carcinoma.

Pathways for Clear Cell Renal Cell Carcinoma

Pathways related to Clear Cell Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 BCL2 CCND1 EGFR HIF1A KDR MET
2
Show member pathways
13.43 BCL2 CCND1 EGFR KDR MET PFKP
3
Show member pathways
13.16 CA9 EPAS1 HIF1A TP53 TSC1 VEGFA
4
Show member pathways
12.94 BCL2 CCND1 EGFR KDR MET RASSF1
5
Show member pathways
12.93 EGFR HIF1A MET SERPINE1 TSC1 VEGFA
6
Show member pathways
12.92 BCL2 CCND1 EGFR KDR MET VEGFA
7
Show member pathways
12.77 BCL2 EPAS1 FLCN HIF1A MET TP53
8
Show member pathways
12.73 EGFR KDR MET RASSF1 VEGFA
9
Show member pathways
12.54 EGFR FLCN KDR MET TP53 TSC1
10 12.48 BCL2 CCND1 EGFR MET RASSF1 TP53
11
Show member pathways
12.47 BCL2 EGFR KDR MET TP53
12
Show member pathways
12.39 EGFR KDR MET VEGFA
13
Show member pathways
12.39 CCND1 MET TP53 TSC1
14 12.39 BCL2 CCND1 EGFR KDR MET TP53
15
Show member pathways
12.35 BCL2 CCND1 EGFR TP53
16 12.31 CA9 EPAS1 FLCN HIF1A TSC1
17
Show member pathways
12.26 BCL2 CCND1 HIF1A TP53
18
Show member pathways
12.25 HIF1A SERPINE1 TP53 VEGFA
19 12.2 CCND1 EGFR TP53 VEGFA
20
Show member pathways
12.19 CCND1 EGFR KDR MET TP53 TSC1
21 12.17 CCND1 EGFR HIF1A KDR MET TP53
22
Show member pathways
12.12 CCND1 EGFR TP53 VEGFA
23 12.11 BCL2 KDR TP53 VEGFA
24 12.1 BCL2 CCND1 SERPINE1 TP53 TSC1
25 12.09 BCL2 EGFR MET SERPINE1 TP53
26
Show member pathways
12.08 CCND1 EGFR EPAS1 HIF1A
27 12.07 BCL2 CCND1 EGFR TP53 TSC1 VEGFA
28 12.02 CCND1 HIF1A PFKP TP53
29 12 BCL2 CCND1 HIF1A TP53 VEGFA
30 11.99 CCND1 EGFR TP53 TSC1
31 11.94 BCL2 CCND1 SERPINE1 VEGFA
32 11.92 BCL2 CCND1 EGFR EPAS1 HIF1A MET
33
Show member pathways
11.89 EPAS1 HIF1A KDR VEGFA VHL
34 11.82 CA9 HIF1A KDR
35 11.81 BCL2 CCND1 TP53
36
Show member pathways
11.77 CCND1 EGFR HIF1A VEGFA
37 11.77 CCND1 EGFR RASSF1 TP53 VEGFA
38 11.73 CA9 HIF1A SERPINE1 VEGFA
39 11.72 BCL2 KDR TP53 VEGFA
40 11.64 HIF1A TP53 VEGFA VHL
41 11.63 BCL2 EGFR HIF1A SERPINE1 VEGFA VHL
42 11.6 CCND1 HIF1A TP53 VEGFA
43 11.59 BCL2 CCND1 EGFR TP53
44 11.58 EGFR HIF1A MET PFKP TP53
45
Show member pathways
11.48 EGFR KDR MET VEGFA
46 11.41 HIF1A SERPINE1 TP53 VEGFA
47 11.19 HIF1A KDR VEGFA
48 11.03 EPAS1 VEGFA VHL
49 10.97 HIF1A TP53 VHL
50 10.89 EPAS1 KDR SERPINE1 VEGFA VHL

GO Terms for Clear Cell Renal Cell Carcinoma

Cellular components related to Clear Cell Renal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.53 BAP1 BCL2 CA9 CCND1 EGFR EPAS1

Biological processes related to Clear Cell Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.87 BCL2 EGFR HIF1A KDR TP53 VEGFA
2 regulation of cell cycle GO:0051726 9.85 BAP1 BCL2 CCND1 TSC1
3 positive regulation of angiogenesis GO:0045766 9.81 HIF1A KDR SERPINE1 VEGFA
4 hemopoiesis GO:0030097 9.8 BCL2 EPAS1 FLCN
5 negative regulation of cell proliferation GO:0008285 9.8 BAP1 BCL2 PBRM1 RNF139 TP53 TSC1
6 positive regulation of endothelial cell proliferation GO:0001938 9.79 HIF1A KDR VEGFA
7 cell morphogenesis GO:0000902 9.77 BCL2 EGFR VHL
8 vasculogenesis GO:0001570 9.77 KDR SETD2 VEGFA
9 positive regulation of protein phosphorylation GO:0001934 9.77 CCND1 EGFR FLCN KDR VEGFA
10 lactation GO:0007595 9.74 CCND1 HIF1A VEGFA
11 negative regulation of TOR signaling GO:0032007 9.7 FLCN HIF1A TSC1
12 positive regulation of macroautophagy GO:0016239 9.67 HIF1A KDR TSC1
13 regulation of cell-matrix adhesion GO:0001952 9.65 BCL2 TSC1
14 positive regulation of focal adhesion assembly GO:0051894 9.65 KDR TSC1 VEGFA
15 growth GO:0040007 9.64 BCL2 VEGFA
16 positive regulation of positive chemotaxis GO:0050927 9.63 KDR VEGFA
17 regulation of mitochondrial membrane permeability GO:0046902 9.63 BCL2 TP53
18 angiogenesis GO:0001525 9.63 EPAS1 HIF1A KDR SERPINE1 SETD2 VEGFA
19 mitotic G1 DNA damage checkpoint GO:0031571 9.62 CCND1 TP53
20 surfactant homeostasis GO:0043129 9.61 EPAS1 VEGFA
21 embryonic placenta development GO:0001892 9.61 EGFR EPAS1 HIF1A
22 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 EPAS1 HIF1A
23 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.58 KDR VEGFA
24 digestive tract morphogenesis GO:0048546 9.58 BCL2 EGFR HIF1A
25 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.56 HIF1A VEGFA
26 response to UV-A GO:0070141 9.54 CCND1 EGFR
27 cellular response to hypoxia GO:0071456 9.35 BCL2 EPAS1 HIF1A TP53 VEGFA
28 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.02 CA9 EPAS1 HIF1A VEGFA VHL
29 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.06 EGFR EPAS1 FLCN HIF1A MET SERPINE1
30 positive regulation of cell proliferation GO:0008284 10.04 BCL2 CCND1 EGFR KDR VEGFA

Molecular functions related to Clear Cell Renal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.8 CCND1 EGFR HIF1A TP53 VHL
2 protein heterodimerization activity GO:0046982 9.8 BCL2 EGFR EPAS1 HIF1A TP53 VEGFA
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.61 EGFR KDR MET
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.46 EGFR KDR
5 protease binding GO:0002020 9.46 BCL2 RNF139 SERPINE1 TP53
6 histone acetyltransferase binding GO:0035035 9.43 EPAS1 HIF1A TP53
7 protein phosphatase binding GO:0019903 9.26 BCL2 EGFR MET TP53
8 transcription factor binding GO:0008134 9.1 BCL2 CCND1 EPAS1 HIF1A TP53 VHL
9 protein binding GO:0005515 10.32 BAP1 BCL2 CCND1 EGFR EPAS1 FLCN

Sources for Clear Cell Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....